AVP-786: Phase III started

Otsuka began the double-blind, placebo-controlled, U.S. Phase III TRIAD-1 trial to evaluate 2 doses of oral AVP-786 twice daily for 12 weeks in about 380 patients. The start of the trial triggered a $...